[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fn_uHTNakIbPerimV8Q9dV4qeoXFtnEZmg-SEMgeBD4w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":33,"phaseBuckets":64,"rows":71},"University of Southampton",[4],119,false,21,5,2257405,11,93,[14,17,19,22,25,27,29,31],{"name":15,"count":16},"Stroke",6,{"name":18,"count":9},"Asthma",{"name":20,"count":21},"Parkinson Disease",4,{"name":23,"count":24},"Chronic Obstructive Pulmonary Disease",3,{"name":26,"count":24},"Chronic Pain",{"name":28,"count":24},"Malnutrition",{"name":30,"count":24},"Colorectal Cancer",{"name":32,"count":24},"Meningitis, Bacterial",[34,39,44,49,54,59],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05965479","Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer","2026-03-31","Trastuzumab deruxtecan",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT05584007","Cellulitis Optimal Antibiotic Treatment","2026-05","Flucloxacillin Only Product in Oral Dose Form",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT05221645","Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed\u002FRefractory Diffuse Large B-cell Lymphoma","2026-05-30","Pembrolizumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT05847322","Periscope Phase C Bordetella Pertussis Human Challenge Study With Delayed Antibiotic Therapy for 6 Weeks","2026-12-01","Bordetella pertussis B1917",{"nctId":55,"briefTitle":56,"date":57,"intervention":58},"NCT07602946","SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma","2027-07","BMS-986504",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT06513065","Study to Evaluate the Non-inferiority of Low-dose HIPEC Versus High-dose HIPEC in the Treatment of PMP (HIPEC-PMP)","2028-09","Mitomycin c",[65,66,67,68,69,70],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[72,96,118,161,200,228,250,268,286,309,343,361,386,410,439,457,475,493,511,539,561,585,615,643,661,688,713,736,760,789,807,825,843,861,879,897,915,933,951,969,987,1005,1038,1062,1080],{"intervention":43,"totalTrials":73,"cells":74},1,{"EARLY_PHASE1":75,"PHASE1":78,"PHASE2":80,"PHASE3":82,"PHASE4":92,"NA":94},{"trials":76,"activeCount":77},[],0,{"trials":79,"activeCount":77},[],{"trials":81,"activeCount":77},[],{"trials":83,"activeCount":73,"soonestReadout":42},[84],{"nctId":40,"briefTitle":41,"status":85,"phases":86,"primaryCompletion":42,"completion":57,"start":87,"enrollment":88,"conditions":89,"interventions":91},"RECRUITING",[68],"2023-08-29",334,[90],"Cellulitis of Leg",[43],{"trials":93,"activeCount":77},[],{"trials":95,"activeCount":77},[],{"intervention":63,"totalTrials":73,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":114,"NA":116},{"trials":99,"activeCount":77},[],{"trials":101,"activeCount":77},[],{"trials":103,"activeCount":77},[],{"trials":105,"activeCount":73,"soonestReadout":62},[106],{"nctId":60,"briefTitle":61,"status":85,"phases":107,"primaryCompletion":62,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":113},[68],"2029-04","2024-12-04",176,[112],"Pseudomyxoma Peritonei",[63],{"trials":115,"activeCount":77},[],{"trials":117,"activeCount":77},[],{"intervention":119,"totalTrials":120,"cells":121},"Rituximab",2,{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":155,"PHASE4":157,"NA":159},{"trials":123,"activeCount":77},[],{"trials":125,"activeCount":77},[],{"trials":127,"activeCount":73,"soonestReadout":47},[128,140],{"nctId":45,"briefTitle":46,"status":129,"phases":130,"primaryCompletion":47,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"ACTIVE_NOT_RECRUITING",[67],"2026-12-31","2022-06-27",65,[135],"Diffuse Large B Cell Lymphoma",[48,119,137,138,139],"Ifosfamide","Carboplatin","Etoposide",{"nctId":141,"briefTitle":142,"status":143,"phases":144,"primaryCompletion":145,"completion":145,"start":146,"enrollment":73,"conditions":147,"interventions":149},"NCT00637832","Rituximab, Combination Chemotherapy, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed Follicular Non-Hodgkin Lymphoma","TERMINATED",[67],"2015-01-06","2008-04-01",[148],"Lymphoma",[150,151,152,153,154],"rituximab","cyclophosphamide","doxorubicin hydrochloride","prednisolone","vincristine sulfate",{"trials":156,"activeCount":77},[],{"trials":158,"activeCount":77},[],{"trials":160,"activeCount":77},[],{"intervention":137,"totalTrials":120,"cells":162},{"EARLY_PHASE1":163,"PHASE1":165,"PHASE2":167,"PHASE3":194,"PHASE4":196,"NA":198},{"trials":164,"activeCount":77},[],{"trials":166,"activeCount":77},[],{"trials":168,"activeCount":73,"soonestReadout":47},[169,173],{"nctId":45,"briefTitle":46,"status":129,"phases":170,"primaryCompletion":47,"completion":131,"start":132,"enrollment":133,"conditions":171,"interventions":172},[67],[135],[48,119,137,138,139],{"nctId":174,"briefTitle":175,"status":176,"phases":177,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":181,"interventions":186},"NCT00551122","Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors","UNKNOWN",[66,67],"2013-04","2006-11",23,[182,183,184,185],"Brain and Central Nervous System Tumors","Extragonadal Germ Cell Tumor","Ovarian Cancer","Testicular Germ Cell Tumor",[187,188,189,190,191,192,193],"filgrastim","lenograstim","pegfilgrastim","cisplatin","gemcitabine hydrochloride","ifosfamide","paclitaxel",{"trials":195,"activeCount":77},[],{"trials":197,"activeCount":77},[],{"trials":199,"activeCount":77},[],{"intervention":138,"totalTrials":120,"cells":201},{"EARLY_PHASE1":202,"PHASE1":204,"PHASE2":206,"PHASE3":222,"PHASE4":224,"NA":226},{"trials":203,"activeCount":77},[],{"trials":205,"activeCount":77},[],{"trials":207,"activeCount":73,"soonestReadout":47},[208,212],{"nctId":45,"briefTitle":46,"status":129,"phases":209,"primaryCompletion":47,"completion":131,"start":132,"enrollment":133,"conditions":210,"interventions":211},[67],[135],[48,119,137,138,139],{"nctId":213,"briefTitle":214,"status":143,"phases":215,"primaryCompletion":216,"completion":216,"start":217,"enrollment":9,"conditions":218,"interventions":220},"NCT00470249","Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer",[67],"2008-11-03","2006-07-15",[219],"Breast Cancer",[138,221],"Gemcitabine Hydrochloride",{"trials":223,"activeCount":77},[],{"trials":225,"activeCount":77},[],{"trials":227,"activeCount":77},[],{"intervention":38,"totalTrials":73,"cells":229},{"EARLY_PHASE1":230,"PHASE1":232,"PHASE2":234,"PHASE3":244,"PHASE4":246,"NA":248},{"trials":231,"activeCount":77},[],{"trials":233,"activeCount":77},[],{"trials":235,"activeCount":73,"soonestReadout":37},[236],{"nctId":35,"briefTitle":36,"status":85,"phases":237,"primaryCompletion":37,"completion":238,"start":239,"enrollment":240,"conditions":241,"interventions":243},[67],"2028-04-30","2024-04-10",25,[242],"Gastrooesophageal Cancer",[38],{"trials":245,"activeCount":77},[],{"trials":247,"activeCount":77},[],{"trials":249,"activeCount":77},[],{"intervention":48,"totalTrials":73,"cells":251},{"EARLY_PHASE1":252,"PHASE1":254,"PHASE2":256,"PHASE3":262,"PHASE4":264,"NA":266},{"trials":253,"activeCount":77},[],{"trials":255,"activeCount":77},[],{"trials":257,"activeCount":73,"soonestReadout":47},[258],{"nctId":45,"briefTitle":46,"status":129,"phases":259,"primaryCompletion":47,"completion":131,"start":132,"enrollment":133,"conditions":260,"interventions":261},[67],[135],[48,119,137,138,139],{"trials":263,"activeCount":77},[],{"trials":265,"activeCount":77},[],{"trials":267,"activeCount":77},[],{"intervention":139,"totalTrials":73,"cells":269},{"EARLY_PHASE1":270,"PHASE1":272,"PHASE2":274,"PHASE3":280,"PHASE4":282,"NA":284},{"trials":271,"activeCount":77},[],{"trials":273,"activeCount":77},[],{"trials":275,"activeCount":73,"soonestReadout":47},[276],{"nctId":45,"briefTitle":46,"status":129,"phases":277,"primaryCompletion":47,"completion":131,"start":132,"enrollment":133,"conditions":278,"interventions":279},[67],[135],[48,119,137,138,139],{"trials":281,"activeCount":77},[],{"trials":283,"activeCount":77},[],{"trials":285,"activeCount":77},[],{"intervention":58,"totalTrials":73,"cells":287},{"EARLY_PHASE1":288,"PHASE1":290,"PHASE2":292,"PHASE3":303,"PHASE4":305,"NA":307},{"trials":289,"activeCount":77},[],{"trials":291,"activeCount":77},[],{"trials":293,"activeCount":73,"soonestReadout":57},[294],{"nctId":55,"briefTitle":56,"status":295,"phases":296,"primaryCompletion":57,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":302},"NOT_YET_RECRUITING",[67],"2027-08","2026-05-11",30,[301],"Mesothelioma",[58],{"trials":304,"activeCount":77},[],{"trials":306,"activeCount":77},[],{"trials":308,"activeCount":77},[],{"intervention":53,"totalTrials":120,"cells":310},{"EARLY_PHASE1":311,"PHASE1":313,"PHASE2":315,"PHASE3":317,"PHASE4":319,"NA":321},{"trials":312,"activeCount":77},[],{"trials":314,"activeCount":77},[],{"trials":316,"activeCount":77},[],{"trials":318,"activeCount":77},[],{"trials":320,"activeCount":77},[],{"trials":322,"activeCount":73,"soonestReadout":52},[323,331],{"nctId":50,"briefTitle":51,"status":85,"phases":324,"primaryCompletion":52,"completion":52,"start":325,"enrollment":326,"conditions":327,"interventions":329},[70],"2022-12-06",72,[328],"Healthy Volunteer Study",[53,330],"Azithromycin Pill",{"nctId":332,"briefTitle":333,"status":176,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":338,"interventions":340},"NCT03751514","Bordetella Pertussis Colonisation Challenge Study",[70],"2021-02-02","2017-05-22",80,[339],"Whooping Cough",[341,342],"Bordetella Pertussis B1917","Azithromycin 500 mg",{"intervention":330,"totalTrials":73,"cells":344},{"EARLY_PHASE1":345,"PHASE1":347,"PHASE2":349,"PHASE3":351,"PHASE4":353,"NA":355},{"trials":346,"activeCount":77},[],{"trials":348,"activeCount":77},[],{"trials":350,"activeCount":77},[],{"trials":352,"activeCount":77},[],{"trials":354,"activeCount":77},[],{"trials":356,"activeCount":73,"soonestReadout":52},[357],{"nctId":50,"briefTitle":51,"status":85,"phases":358,"primaryCompletion":52,"completion":52,"start":325,"enrollment":326,"conditions":359,"interventions":360},[70],[328],[53,330],{"intervention":362,"totalTrials":73,"cells":363},"Seretide 500 Accuhaler",{"EARLY_PHASE1":364,"PHASE1":366,"PHASE2":368,"PHASE3":370,"PHASE4":372,"NA":384},{"trials":365,"activeCount":77},[],{"trials":367,"activeCount":77},[],{"trials":369,"activeCount":77},[],{"trials":371,"activeCount":77},[],{"trials":373,"activeCount":77},[374],{"nctId":375,"briefTitle":376,"status":377,"phases":378,"primaryCompletion":379,"completion":379,"start":380,"enrollment":381,"conditions":382,"interventions":383},"NCT00974805","An Investigation of the Mechanism of Action of Seretide in Chronic Obstructive Pulmonary Disease","COMPLETED",[69],"2012-02","2010-02",48,[23],[362],{"trials":385,"activeCount":77},[],{"intervention":387,"totalTrials":73,"cells":388},"Nivolumab",{"EARLY_PHASE1":389,"PHASE1":391,"PHASE2":393,"PHASE3":395,"PHASE4":406,"NA":408},{"trials":390,"activeCount":77},[],{"trials":392,"activeCount":77},[],{"trials":394,"activeCount":77},[],{"trials":396,"activeCount":77},[397],{"nctId":398,"briefTitle":399,"status":377,"phases":400,"primaryCompletion":401,"completion":401,"start":402,"enrollment":403,"conditions":404,"interventions":405},"NCT03063450","CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma",[68],"2023-02-07","2017-03-28",332,[301],[387],{"trials":407,"activeCount":77},[],{"trials":409,"activeCount":77},[],{"intervention":411,"totalTrials":73,"cells":412},"cetuximab",{"EARLY_PHASE1":413,"PHASE1":415,"PHASE2":417,"PHASE3":419,"PHASE4":435,"NA":437},{"trials":414,"activeCount":77},[],{"trials":416,"activeCount":77},[],{"trials":418,"activeCount":77},[],{"trials":420,"activeCount":77},[421],{"nctId":422,"briefTitle":423,"status":176,"phases":424,"primaryCompletion":425,"start":426,"enrollment":427,"conditions":428,"interventions":430},"NCT00482222","Combination Chemotherapy With or Without Cetuximab Before and After Surgery in Treating Patients With Resectable Liver Metastases Caused By Colorectal Cancer",[68],"2014-12","2007-02",340,[30,429],"Metastatic Cancer",[411,431,432,433,434],"capecitabine","fluorouracil","leucovorin calcium","oxaliplatin",{"trials":436,"activeCount":77},[],{"trials":438,"activeCount":77},[],{"intervention":431,"totalTrials":73,"cells":440},{"EARLY_PHASE1":441,"PHASE1":443,"PHASE2":445,"PHASE3":447,"PHASE4":453,"NA":455},{"trials":442,"activeCount":77},[],{"trials":444,"activeCount":77},[],{"trials":446,"activeCount":77},[],{"trials":448,"activeCount":77},[449],{"nctId":422,"briefTitle":423,"status":176,"phases":450,"primaryCompletion":425,"start":426,"enrollment":427,"conditions":451,"interventions":452},[68],[30,429],[411,431,432,433,434],{"trials":454,"activeCount":77},[],{"trials":456,"activeCount":77},[],{"intervention":432,"totalTrials":73,"cells":458},{"EARLY_PHASE1":459,"PHASE1":461,"PHASE2":463,"PHASE3":465,"PHASE4":471,"NA":473},{"trials":460,"activeCount":77},[],{"trials":462,"activeCount":77},[],{"trials":464,"activeCount":77},[],{"trials":466,"activeCount":77},[467],{"nctId":422,"briefTitle":423,"status":176,"phases":468,"primaryCompletion":425,"start":426,"enrollment":427,"conditions":469,"interventions":470},[68],[30,429],[411,431,432,433,434],{"trials":472,"activeCount":77},[],{"trials":474,"activeCount":77},[],{"intervention":433,"totalTrials":73,"cells":476},{"EARLY_PHASE1":477,"PHASE1":479,"PHASE2":481,"PHASE3":483,"PHASE4":489,"NA":491},{"trials":478,"activeCount":77},[],{"trials":480,"activeCount":77},[],{"trials":482,"activeCount":77},[],{"trials":484,"activeCount":77},[485],{"nctId":422,"briefTitle":423,"status":176,"phases":486,"primaryCompletion":425,"start":426,"enrollment":427,"conditions":487,"interventions":488},[68],[30,429],[411,431,432,433,434],{"trials":490,"activeCount":77},[],{"trials":492,"activeCount":77},[],{"intervention":434,"totalTrials":73,"cells":494},{"EARLY_PHASE1":495,"PHASE1":497,"PHASE2":499,"PHASE3":501,"PHASE4":507,"NA":509},{"trials":496,"activeCount":77},[],{"trials":498,"activeCount":77},[],{"trials":500,"activeCount":77},[],{"trials":502,"activeCount":77},[503],{"nctId":422,"briefTitle":423,"status":176,"phases":504,"primaryCompletion":425,"start":426,"enrollment":427,"conditions":505,"interventions":506},[68],[30,429],[411,431,432,433,434],{"trials":508,"activeCount":77},[],{"trials":510,"activeCount":77},[],{"intervention":512,"totalTrials":73,"cells":513},"Aspirin",{"EARLY_PHASE1":514,"PHASE1":516,"PHASE2":518,"PHASE3":520,"PHASE4":535,"NA":537},{"trials":515,"activeCount":77},[],{"trials":517,"activeCount":77},[],{"trials":519,"activeCount":77},[],{"trials":521,"activeCount":77},[522],{"nctId":523,"briefTitle":524,"status":143,"phases":525,"primaryCompletion":526,"completion":527,"start":528,"enrollment":529,"conditions":530,"interventions":534},"NCT03796156","Aspirin to Target Arterial Events in Chronic Kidney Disease",[68],"2024-09-30","2025-09-23","2019-02-25",4633,[531,532,533],"Chronic Kidney Diseases","Cardiovascular Diseases","Bleeding",[512],{"trials":536,"activeCount":77},[],{"trials":538,"activeCount":77},[],{"intervention":221,"totalTrials":120,"cells":540},{"EARLY_PHASE1":541,"PHASE1":543,"PHASE2":545,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":542,"activeCount":77},[],{"trials":544,"activeCount":77},[],{"trials":546,"activeCount":77},[547,551],{"nctId":213,"briefTitle":214,"status":143,"phases":548,"primaryCompletion":216,"completion":216,"start":217,"enrollment":9,"conditions":549,"interventions":550},[67],[219],[138,221],{"nctId":174,"briefTitle":175,"status":176,"phases":552,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":553,"interventions":554},[66,67],[182,183,184,185],[187,188,189,190,191,192,193],{"trials":556,"activeCount":77},[],{"trials":558,"activeCount":77},[],{"trials":560,"activeCount":77},[],{"intervention":562,"totalTrials":73,"cells":563},"melphalan",{"EARLY_PHASE1":564,"PHASE1":566,"PHASE2":568,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":565,"activeCount":77},[],{"trials":567,"activeCount":77},[],{"trials":569,"activeCount":77},[570],{"nctId":571,"briefTitle":572,"status":143,"phases":573,"primaryCompletion":574,"completion":574,"start":575,"enrollment":240,"conditions":576,"interventions":578},"NCT00637767","High-Dose Melphalan With or Without Radiolabeled Monoclonal Antibody in Treating Patients With Multiple Myeloma Undergoing an Autologous Stem Cell Transplant",[67],"2013-10-31","2007-12-01",[577],"Multiple Myeloma and Plasma Cell Neoplasm",[562],{"trials":580,"activeCount":77},[],{"trials":582,"activeCount":77},[],{"trials":584,"activeCount":77},[],{"intervention":586,"totalTrials":73,"cells":587},"BNT113",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":609,"PHASE4":611,"NA":613},{"trials":589,"activeCount":77},[],{"trials":591,"activeCount":77},[],{"trials":593,"activeCount":77},[594],{"nctId":595,"briefTitle":596,"status":377,"phases":597,"primaryCompletion":598,"completion":599,"start":600,"enrollment":601,"conditions":602,"interventions":608},"NCT03418480","HARE-40: HPV Anti-CD40 RNA vaccinE",[66,67],"2023-11-01","2024-01-24","2017-04-11",32,[603,604,605,606,607],"Human Papilloma Virus Related Carcinoma","Head and Neck Neoplasm","Cervical Neoplasm","Penile Neoplasms Malignant","Unknown Primary Tumors",[586],{"trials":610,"activeCount":77},[],{"trials":612,"activeCount":77},[],{"trials":614,"activeCount":77},[],{"intervention":616,"totalTrials":73,"cells":617},"House dust-mite SLIT",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":637,"PHASE4":639,"NA":641},{"trials":619,"activeCount":77},[],{"trials":621,"activeCount":77},[],{"trials":623,"activeCount":77},[624],{"nctId":625,"briefTitle":626,"status":377,"phases":627,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":632,"interventions":635},"NCT03763630","MAPS & ITEC Cohorts: 6-8 Years Follow-up",[67],"2018-12-05","2019-01-15","2017-09-15",263,[633,634,18],"Immunotherapy","Allergy and Immunology",[616,636],"Normal saline",{"trials":638,"activeCount":77},[],{"trials":640,"activeCount":77},[],{"trials":642,"activeCount":77},[],{"intervention":636,"totalTrials":73,"cells":644},{"EARLY_PHASE1":645,"PHASE1":647,"PHASE2":649,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":646,"activeCount":77},[],{"trials":648,"activeCount":77},[],{"trials":650,"activeCount":77},[651],{"nctId":625,"briefTitle":626,"status":377,"phases":652,"primaryCompletion":628,"completion":629,"start":630,"enrollment":631,"conditions":653,"interventions":654},[67],[633,634,18],[616,636],{"trials":656,"activeCount":77},[],{"trials":658,"activeCount":77},[],{"trials":660,"activeCount":77},[],{"intervention":662,"totalTrials":73,"cells":663},"Devil Claw",{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":682,"PHASE4":684,"NA":686},{"trials":665,"activeCount":77},[],{"trials":667,"activeCount":77},[],{"trials":669,"activeCount":77},[670],{"nctId":671,"briefTitle":672,"status":143,"phases":673,"primaryCompletion":674,"completion":675,"start":676,"enrollment":677,"conditions":678,"interventions":681},"NCT00295490","Trial Evaluating Devil's Claw for the Treatment of Hip and Knee Osteoarthritis",[67],"2007-11","2008-06","2004-12",67,[679,680],"Osteoarthritis, Knee","Osteoarthritis, Hip",[662],{"trials":683,"activeCount":77},[],{"trials":685,"activeCount":77},[],{"trials":687,"activeCount":77},[],{"intervention":689,"totalTrials":73,"cells":690},"Etanercept",{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":707,"PHASE4":709,"NA":711},{"trials":692,"activeCount":77},[],{"trials":694,"activeCount":77},[],{"trials":696,"activeCount":77},[697],{"nctId":698,"briefTitle":699,"status":377,"phases":700,"primaryCompletion":701,"start":702,"enrollment":703,"conditions":704,"interventions":706},"NCT01068353","Safety and Tolerability of Etanercept in Alzheimer's Disease",[67],"2013-12","2011-01",41,[705],"Alzheimer's Disease",[689],{"trials":708,"activeCount":77},[],{"trials":710,"activeCount":77},[],{"trials":712,"activeCount":77},[],{"intervention":714,"totalTrials":73,"cells":715},"PD-1 vaccine IMU-201",{"EARLY_PHASE1":716,"PHASE1":718,"PHASE2":720,"PHASE3":730,"PHASE4":732,"NA":734},{"trials":717,"activeCount":77},[],{"trials":719,"activeCount":77},[],{"trials":721,"activeCount":77},[722],{"nctId":723,"briefTitle":724,"status":143,"phases":725,"primaryCompletion":726,"completion":726,"start":727,"enrollment":24,"conditions":728,"interventions":729},"NCT06692959","A Phase II Trial of Neoadjuvant PD-1 Vaccine PD1-Vaxx in Operable MSI High Colorectal Cancer",[67],"2026-05-28","2025-06-16",[30],[714],{"trials":731,"activeCount":77},[],{"trials":733,"activeCount":77},[],{"trials":735,"activeCount":77},[],{"intervention":737,"totalTrials":73,"cells":738},"Clopidogrel",{"EARLY_PHASE1":739,"PHASE1":741,"PHASE2":743,"PHASE3":754,"PHASE4":756,"NA":758},{"trials":740,"activeCount":77},[],{"trials":742,"activeCount":77},[],{"trials":744,"activeCount":77},[745],{"nctId":746,"briefTitle":747,"status":377,"phases":748,"primaryCompletion":749,"completion":749,"start":750,"enrollment":751,"conditions":752,"interventions":753},"NCT01955512","Effect of Clopidogrel on Allergen Challenge in Asthma",[67],"2014-05","2013-05",24,[18],[737],{"trials":755,"activeCount":77},[],{"trials":757,"activeCount":77},[],{"trials":759,"activeCount":77},[],{"intervention":761,"totalTrials":73,"cells":762},"Temozolomide",{"EARLY_PHASE1":763,"PHASE1":765,"PHASE2":767,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":764,"activeCount":77},[],{"trials":766,"activeCount":77},[],{"trials":768,"activeCount":77},[769],{"nctId":770,"briefTitle":771,"status":377,"phases":772,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":776,"interventions":779},"NCT04984733","Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer",[67],"2024-10-23","2021-09-28",13,[777,778],"Adenocarcinoma - GEJ","Cancer of Esophagus",[761,780,781,782],"Temozolomide 50mg\u002Fm2\u002Fday","Temozolomide 3 month","Temozolomide 24month",{"trials":784,"activeCount":77},[],{"trials":786,"activeCount":77},[],{"trials":788,"activeCount":77},[],{"intervention":780,"totalTrials":73,"cells":790},{"EARLY_PHASE1":791,"PHASE1":793,"PHASE2":795,"PHASE3":801,"PHASE4":803,"NA":805},{"trials":792,"activeCount":77},[],{"trials":794,"activeCount":77},[],{"trials":796,"activeCount":77},[797],{"nctId":770,"briefTitle":771,"status":377,"phases":798,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":799,"interventions":800},[67],[777,778],[761,780,781,782],{"trials":802,"activeCount":77},[],{"trials":804,"activeCount":77},[],{"trials":806,"activeCount":77},[],{"intervention":781,"totalTrials":73,"cells":808},{"EARLY_PHASE1":809,"PHASE1":811,"PHASE2":813,"PHASE3":819,"PHASE4":821,"NA":823},{"trials":810,"activeCount":77},[],{"trials":812,"activeCount":77},[],{"trials":814,"activeCount":77},[815],{"nctId":770,"briefTitle":771,"status":377,"phases":816,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":817,"interventions":818},[67],[777,778],[761,780,781,782],{"trials":820,"activeCount":77},[],{"trials":822,"activeCount":77},[],{"trials":824,"activeCount":77},[],{"intervention":782,"totalTrials":73,"cells":826},{"EARLY_PHASE1":827,"PHASE1":829,"PHASE2":831,"PHASE3":837,"PHASE4":839,"NA":841},{"trials":828,"activeCount":77},[],{"trials":830,"activeCount":77},[],{"trials":832,"activeCount":77},[833],{"nctId":770,"briefTitle":771,"status":377,"phases":834,"primaryCompletion":773,"completion":773,"start":774,"enrollment":775,"conditions":835,"interventions":836},[67],[777,778],[761,780,781,782],{"trials":838,"activeCount":77},[],{"trials":840,"activeCount":77},[],{"trials":842,"activeCount":77},[],{"intervention":151,"totalTrials":73,"cells":844},{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":855,"PHASE4":857,"NA":859},{"trials":846,"activeCount":77},[],{"trials":848,"activeCount":77},[],{"trials":850,"activeCount":77},[851],{"nctId":141,"briefTitle":142,"status":143,"phases":852,"primaryCompletion":145,"completion":145,"start":146,"enrollment":73,"conditions":853,"interventions":854},[67],[148],[150,151,152,153,154],{"trials":856,"activeCount":77},[],{"trials":858,"activeCount":77},[],{"trials":860,"activeCount":77},[],{"intervention":152,"totalTrials":73,"cells":862},{"EARLY_PHASE1":863,"PHASE1":865,"PHASE2":867,"PHASE3":873,"PHASE4":875,"NA":877},{"trials":864,"activeCount":77},[],{"trials":866,"activeCount":77},[],{"trials":868,"activeCount":77},[869],{"nctId":141,"briefTitle":142,"status":143,"phases":870,"primaryCompletion":145,"completion":145,"start":146,"enrollment":73,"conditions":871,"interventions":872},[67],[148],[150,151,152,153,154],{"trials":874,"activeCount":77},[],{"trials":876,"activeCount":77},[],{"trials":878,"activeCount":77},[],{"intervention":153,"totalTrials":73,"cells":880},{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":891,"PHASE4":893,"NA":895},{"trials":882,"activeCount":77},[],{"trials":884,"activeCount":77},[],{"trials":886,"activeCount":77},[887],{"nctId":141,"briefTitle":142,"status":143,"phases":888,"primaryCompletion":145,"completion":145,"start":146,"enrollment":73,"conditions":889,"interventions":890},[67],[148],[150,151,152,153,154],{"trials":892,"activeCount":77},[],{"trials":894,"activeCount":77},[],{"trials":896,"activeCount":77},[],{"intervention":154,"totalTrials":73,"cells":898},{"EARLY_PHASE1":899,"PHASE1":901,"PHASE2":903,"PHASE3":909,"PHASE4":911,"NA":913},{"trials":900,"activeCount":77},[],{"trials":902,"activeCount":77},[],{"trials":904,"activeCount":77},[905],{"nctId":141,"briefTitle":142,"status":143,"phases":906,"primaryCompletion":145,"completion":145,"start":146,"enrollment":73,"conditions":907,"interventions":908},[67],[148],[150,151,152,153,154],{"trials":910,"activeCount":77},[],{"trials":912,"activeCount":77},[],{"trials":914,"activeCount":77},[],{"intervention":187,"totalTrials":73,"cells":916},{"EARLY_PHASE1":917,"PHASE1":919,"PHASE2":921,"PHASE3":927,"PHASE4":929,"NA":931},{"trials":918,"activeCount":77},[],{"trials":920,"activeCount":77},[],{"trials":922,"activeCount":77},[923],{"nctId":174,"briefTitle":175,"status":176,"phases":924,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":925,"interventions":926},[66,67],[182,183,184,185],[187,188,189,190,191,192,193],{"trials":928,"activeCount":77},[],{"trials":930,"activeCount":77},[],{"trials":932,"activeCount":77},[],{"intervention":188,"totalTrials":73,"cells":934},{"EARLY_PHASE1":935,"PHASE1":937,"PHASE2":939,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":936,"activeCount":77},[],{"trials":938,"activeCount":77},[],{"trials":940,"activeCount":77},[941],{"nctId":174,"briefTitle":175,"status":176,"phases":942,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":943,"interventions":944},[66,67],[182,183,184,185],[187,188,189,190,191,192,193],{"trials":946,"activeCount":77},[],{"trials":948,"activeCount":77},[],{"trials":950,"activeCount":77},[],{"intervention":189,"totalTrials":73,"cells":952},{"EARLY_PHASE1":953,"PHASE1":955,"PHASE2":957,"PHASE3":963,"PHASE4":965,"NA":967},{"trials":954,"activeCount":77},[],{"trials":956,"activeCount":77},[],{"trials":958,"activeCount":77},[959],{"nctId":174,"briefTitle":175,"status":176,"phases":960,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":961,"interventions":962},[66,67],[182,183,184,185],[187,188,189,190,191,192,193],{"trials":964,"activeCount":77},[],{"trials":966,"activeCount":77},[],{"trials":968,"activeCount":77},[],{"intervention":190,"totalTrials":73,"cells":970},{"EARLY_PHASE1":971,"PHASE1":973,"PHASE2":975,"PHASE3":981,"PHASE4":983,"NA":985},{"trials":972,"activeCount":77},[],{"trials":974,"activeCount":77},[],{"trials":976,"activeCount":77},[977],{"nctId":174,"briefTitle":175,"status":176,"phases":978,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":979,"interventions":980},[66,67],[182,183,184,185],[187,188,189,190,191,192,193],{"trials":982,"activeCount":77},[],{"trials":984,"activeCount":77},[],{"trials":986,"activeCount":77},[],{"intervention":193,"totalTrials":73,"cells":988},{"EARLY_PHASE1":989,"PHASE1":991,"PHASE2":993,"PHASE3":999,"PHASE4":1001,"NA":1003},{"trials":990,"activeCount":77},[],{"trials":992,"activeCount":77},[],{"trials":994,"activeCount":77},[995],{"nctId":174,"briefTitle":175,"status":176,"phases":996,"primaryCompletion":178,"start":179,"enrollment":180,"conditions":997,"interventions":998},[66,67],[182,183,184,185],[187,188,189,190,191,192,193],{"trials":1000,"activeCount":77},[],{"trials":1002,"activeCount":77},[],{"trials":1004,"activeCount":77},[],{"intervention":1006,"totalTrials":120,"cells":1007},"N. lactamica",{"EARLY_PHASE1":1008,"PHASE1":1028,"PHASE2":1030,"PHASE3":1032,"PHASE4":1034,"NA":1036},{"trials":1009,"activeCount":77},[1010,1019],{"nctId":1011,"briefTitle":1012,"status":377,"phases":1013,"primaryCompletion":1014,"completion":1014,"start":1015,"enrollment":1016,"conditions":1017,"interventions":1018},"NCT03633474","Defining the Immune Response to Nasopharyngeal Colonisation by the Commensal Neisseria Lactamica",[65],"2019-09-01","2018-09-01",31,[32],[1006],{"nctId":1020,"briefTitle":1021,"status":377,"phases":1022,"primaryCompletion":1014,"completion":1014,"start":1023,"enrollment":1024,"conditions":1025,"interventions":1027},"NCT03630250","Challenge of the Nasopharynx With Neisseria Lactamica Expressing the Meningococcal Protein Neisseria Adhesin A (NadA)",[65],"2018-10-18",35,[32,1026],"Neisseria Infection",[1006],{"trials":1029,"activeCount":77},[],{"trials":1031,"activeCount":77},[],{"trials":1033,"activeCount":77},[],{"trials":1035,"activeCount":77},[],{"trials":1037,"activeCount":77},[],{"intervention":1039,"totalTrials":73,"cells":1040},"Lyophilised Neisseria lactamica",{"EARLY_PHASE1":1041,"PHASE1":1043,"PHASE2":1045,"PHASE3":1047,"PHASE4":1049,"NA":1051},{"trials":1042,"activeCount":77},[],{"trials":1044,"activeCount":77},[],{"trials":1046,"activeCount":77},[],{"trials":1048,"activeCount":77},[],{"trials":1050,"activeCount":77},[],{"trials":1052,"activeCount":77},[1053],{"nctId":1054,"briefTitle":1055,"status":176,"phases":1056,"primaryCompletion":1057,"completion":1058,"start":1059,"enrollment":1024,"conditions":1060,"interventions":1061},"NCT04135053","A Controlled Study to Assess Safety, Colonisation and Immunogenicity of Reconstituted Lyophilised Neisseria Lactamica",[70],"2020-02-01","2021-12-31","2019-02-01",[32],[1039],{"intervention":342,"totalTrials":73,"cells":1063},{"EARLY_PHASE1":1064,"PHASE1":1066,"PHASE2":1068,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1065,"activeCount":77},[],{"trials":1067,"activeCount":77},[],{"trials":1069,"activeCount":77},[],{"trials":1071,"activeCount":77},[],{"trials":1073,"activeCount":77},[],{"trials":1075,"activeCount":77},[1076],{"nctId":332,"briefTitle":333,"status":176,"phases":1077,"primaryCompletion":335,"completion":335,"start":336,"enrollment":337,"conditions":1078,"interventions":1079},[70],[339],[341,342],{"intervention":1081,"totalTrials":73,"cells":1082},"N. lactamica Y92-1009",{"EARLY_PHASE1":1083,"PHASE1":1085,"PHASE2":1087,"PHASE3":1089,"PHASE4":1091,"NA":1093},{"trials":1084,"activeCount":77},[],{"trials":1086,"activeCount":77},[],{"trials":1088,"activeCount":77},[],{"trials":1090,"activeCount":77},[],{"trials":1092,"activeCount":77},[],{"trials":1094,"activeCount":77},[1095],{"nctId":1096,"briefTitle":1097,"status":377,"phases":1098,"primaryCompletion":1099,"completion":1099,"start":1100,"enrollment":1016,"conditions":1101,"interventions":1103},"NCT04784845","Lactamica 9: Neisseria Lactamica Inoculation in Late Pregnancy",[70],"2022-07-12","2021-10-01",[1102],"Microbial Colonization",[1081]]